Insights

Professional
Practice
Industry
Region
Trending Topics
Location
Type

Sort by:

Firm News 2 results

Firm News | 1 min read | 06.03.24

The American Bar Association Names Judy He to 2024 “On the Rise” List

Judy He, a Chicago-based counsel in Crowell & Moring’s Patents Group, has been named to the American Bar Association’s 2024 “On the Rise” list. The awards honor young ABA members “who exemplify a broad range of high achievement, innovation, vision, leadership, and legal and community service.”

Firm News | 10 min read | 01.09.23

Crowell & Moring Elects 16 New Partners, Promotes Five to Senior Counsel, and 25 to Counsel

Crowell & Moring elected 16 lawyers to the firm’s partnership, effective January 1, 2023. The firm also promoted five lawyers to the position of senior counsel and 25 associates to the position of counsel.

Client Alerts 14 results

Client Alert | 4 min read | 04.18.24

Maryland and Colorado Say the Price Isn’t Right: State Drug Affordability Review Boards Seek Drug Upper Payment Limits

Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2] 
...

Client Alert | 5 min read | 03.05.24

A Winning Streak? IRA’s Drug Price Negotiation Program Survives Again

On March 1, 2024, Judge Colm F. Connolly of the District of Delaware granted the government’s motion for summary judgment in the first substantive ruling on the constitutionality of the Inflation Reduction Act (“IRA”).  The court first held that AstraZeneca Pharmaceuticals LP and AstraZeneca AB’s (collectively, “AstraZeneca”) lacked Article III standing to challenge the Center for Medicare and Medicaid Services’ (“CMS”) guidance under the Administrative Procedure Act (“APA”).  The court then rejected AstraZeneca’s challenge to the IRA as an unconstitutional taking on the merits because, in its view, AstraZeneca “ha[d] not identified a property interest protected by the Constitution that is put in jeopardy by the Program.”[1] The court’s opinion comes on the eve of oral argument in a closely-followed related case in the District of New Jersey and marks a significant development in IRA jurisprudence.
...

Client Alert | 4 min read | 02.20.24

Western District of Texas Dismisses Constitutional Challenges to IRA’s Drug Price Negotiation Program for Lack of Subject Matter Jurisdiction and Venue

On February 12, 2024, Judge David Alan Ezra of the Western District of Texas dismissed a lawsuit challenging the constitutionality of the Drug Price Negotiation Program of the Inflation Reduction Act of 2022, P.L. 177-169 (IRA).[1]
...

Publications 3 results

Publication | 01.31.20

Patents and the Federal Circuit, Fourteenth Edition

Bloomberg Law